Business
NeuroOne CEO Joins Today’s Marketplace To Discuss The Latest Treatments for Epilepsy
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) CEO Dave Rosa and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today’s Marketplace host Elizabeth Hart to discuss the latest treatments for epilepsy The full interview can be viewed online here. “Epilepsy is a neurological condition," explained Dr. Clark. “Right now we are
About this update from Neuroone Medical Technologies Corporation
[{"type":"image","alt":"Today's Marketplace","displaySize":"","headline":null,"caption":"Today's Marketplace","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/97b88e39afce99baf7fef8515a6d4202"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zi9wVOfBhOhrQXnlg42qCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/97b88e39afce99baf7fef8515a6d4202","width":300,"height":300}},"lazy":false},{"type":"text","content":"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) CEO Dave Rosa and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today’s Marketplace host Elizabeth Hart to discuss the latest treatments for epilepsy","length":384,"tagName":"p"},{"type":"text","content":"The full interview can be viewed online here.","length":45,"tagName":"p"},{"type":"text","content":"“Epilepsy is a neurological condition," explained Dr. Clark. “Right now we are looking at about fifty million people worldwide impacted by it. Epilepsy can affect anyone at any time, and in the US today, we have over three million people diagnosed with the condition."","length":278,"tagName":"p"},{"type":"text","content":"Dr. Clark went on to explain to Hart that there are many treatment options available for people with epilepsy today, and most sufferers can manage their seizures well with pharmaceuticals. However, approximately one-third of epilepsy patients do not react well to current antiseizure medications, which leaves roughly one million people in need of other nonpharmaceutical forms of treatment.","length":391,"tagName":"p"},{"type":"text","content":"Mr. Rosa described this group of patients seeking non-drug options for the management of epilepsy as exactly the patient population NeuroOne is addressing.","length":155,"tagName":"p"},{"type":"text","content":"Addressing this critical need, NeuroOne has developed the OneRF™ ablation system, the first and only FDA 510(k)-cleared device capable of both recording brain activity and performing an RF ablation using the same device. The system has three main components: an electrode that records and monitors brain ...